Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

ARQT

Pozycja w akcjach #4062
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Cena akcji
$31.91
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$4.01B
Zmiana (1 dzień)
-2.77%
Zmiana (1 rok)
61.08%
Kraj
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)

Kategoria

Healthcare
Historia ceny akcji dla Arcutis Biotherapeutics, Inc. (ARQT)
Najwyższa cena zamknięcia: $27.20 dnia 2026-10-01

Najniższa cena zamknięcia: $21.80 dnia 2020-01-01
Historia cen akcji firmy Arcutis Biotherapeutics, Inc. od 2020 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) -13.06%
2025 117.39%
2024 438.98%
2023 -84.13%
2022 -9.27%
2021 -38.74%
2020 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$527.18 23.62%
US
$251.29 835.90%
US
$137.07 -4.31%
AU
$890.85 9.42%
NL
$752.87 7.01%
CH